Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment

The Cigna Group CI recently announced that it will start covering RhinAer, a minimally invasive solution for chronic rhinitis, starting Sept. 15, 2025. This move highlights the increasing confidence in patient options for dealing with nasal issues like congestion and rhinorrhea. This is a significant step forward for both patients and healthcare providers, as it takes RhinAer off CI’s list of experimental or investigational treatments, granting access to more than 15 million members across the country.RhinAer, developed by Aerin Medical, is an innovative treatment that utilizes temperature-controlled radiofrequency technology to target the posterior nasal nerve. Unlike traditional surgical approaches, RhinAer is incisionless, only requires local anesthesia, and can conveniently be done during a regular office visit. This treatment has already benefited more than 50,000 individuals.This strategic move confirms RhinAer’s clinical effectiveness, backed by more than 20 peer-reviewed studies and three years of outcome data. CI’s recent policy update underscores the increasing acknowledgment of RhinAer’s clinical efficacy and overall health benefits as a non-invasive option, standing out against surgery or long-term medications as well as traditional clinic-based management.This increases the company’s value as a player that supports minimally invasive and evidence-based treatments. By reducing the need for invasive procedures or continuous medications, it is consistent with CI’s dedication to member-focused care and cost containment.Cigna’s inclusion of RhinAer in its coverage option is an innovative step in revolutionizing care for those suffering from chronic rhinitis. CI’s choice positions it as a forward-thinking leader in patient-focused health coverage. In 2024, the company delivered more than 8 million prescriptions to more than a million patients through its own operational assets and expertise, which include the careful mixing and preparation of medications in sterile environments that take years to develop and are fully licensed.CI Stock Price PerformanceOver the past year, CI shares have risen 0.3% against the industry’s fall of 29.7%.Image Source: Zacks Investment ResearchCI’s Zacks Rank & Key PicksCI currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the Medical space are Clover Health Investments Corp CLOV, Fresenius Medical Care AG & Co. FMS and BrightSpring Health Services, Inc. BTSG, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Clover Health Investments’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. Clover Health Investments beat earnings estimates in each of the trailing four quarters, with the average surprise being 114.6%. The consensus estimate for current-year revenues is pegged at $1.9 billion, indicating 37.7% year-over-year growth.The Zacks Consensus Estimate for Fresenius Medical Care AG & Co.’s current-year earnings of $2.21 per share has witnessed three upward revisions in the past 30 days against no movement in the opposite direction. Fresenius Medical Care AG & Co. beat earnings estimates in three of the trailing four quarters and met once, with the average surprise being 6.6%. The consensus estimate for current-year revenues is pegged at $21.9 billion, indicating 4.8% year-over-year growth.The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.02 per share has witnessed five upward revisions in the past 60 days against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in two of the trailing four quarters and missed twice, with an average surprise being 17.5%. The consensus estimate for current-year revenues is pegged at $12.3 billion, implying 9.1% year-over-year growth.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI): Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS): Free Stock Analysis Report Clover Health Investments, Corp. (CLOV): Free Stock Analysis Report BrightSpring Health Services, Inc. (BTSG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks